Rigel Pharmaceuticals vs UroGen Pharma
RIGL and URGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RIGL and URGN compare
UroGen Pharma is the larger company, worth 1.5 times as much as Rigel Pharmaceuticals ($1.3B against $831M).
UroGen Pharma grew revenue faster over the last twelve months (159% versus 2.2% for Rigel Pharmaceuticals).
Rigel Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 107% compared with −26.3% at UroGen Pharma.
Rigel Pharmaceuticals scores higher on the StockData Score (11 against 6 for UroGen Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RIGL | URGN |
|---|---|---|
| Size and price | ||
| Market cap | $831M | $1.3B |
| Share price | $44.46 | $26.18 |
| Change, 1 year | 11.3% | 4.1% |
| Change, 5 years | 45.8% | 117% |
| Beta (5Y) | 1.08 | 0.87 |
| Employees | 174 | 291 |
| StockData Score | ||
| Total score | 11 (better) | 6 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 4 (better) | 2 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 2.9× | – |
| P/S | 2.9× (better) | 5.1× |
| P/B | 1.9× | – |
| EV/EBITDA | 9.2× | – |
| FCF yield | – | −10.3% |
| Growth | ||
| Revenue growth (TTM) | 2.2% | 159% (better) |
| Revenue growth, 5Y average | 22.1% | 56.2% (better) |
| Net income growth (TTM) | 171% | – |
| EPS growth (TTM) | 147% | – |
| Profitability | ||
| Gross margin | 89.6% | 91.4% (better) |
| Operating margin | 26.3% (better) | −12.4% |
| Net margin | 107% (better) | −26.3% |
| FCF margin | – | −52.8% |
| Return on equity | 109% | – |
| Return on invested capital | 46.4% | – |
| Financial health | ||
| Interest coverage | 18.2× | – |
| Current ratio | 2.39 | 3.40 (better) |
| Altman Z-score | 4.98 (better) | −1.88 |
| Piotroski F-score | 7 (better) | 0 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 87.7% | 86.8% |
| Held by insiders | 3.3% | 5.6% |
| Insider net buying, 12 months | −$306K (better) | −$4.5M |
| Short interest, % of float | 14.0% | 11.1% |
Go deeper
- RIGL stock overview
- RIGL income statement
- RIGL valuation and score
- URGN stock overview
- URGN income statement
- URGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.